BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 36172352)

  • 1. Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder.
    Nie G; Sun L; Zhang C; Yuan Y; Mao H; Wang Z; Li J; Duan S; Xing C; Zhang B
    Front Immunol; 2022; 13():903315. PubMed ID: 36172352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.
    Higgins L; Nasr SH; Said SM; Kapoor P; Dingli D; King RL; Rajkumar SV; Kyle RA; Kourelis T; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Ansell SM; Gonsalves WI; Thompson CA; Fervenza FC; Zand L; Hwa YL; Jevremovic D; Shi M; Leung N
    Clin J Am Soc Nephrol; 2018 Jul; 13(7):1037-1046. PubMed ID: 29848505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders.
    Javaugue V; Debiais-Delpech C; Nouvier M; Gand E; Chauvet S; Ecotiere L; Desport E; Goujon JM; Delwail V; Guidez S; Tomowiak C; Leleu X; Jaccard A; Rioux-Leclerc N; Vigneau C; Fermand JP; Touchard G; Thierry A; Bridoux F
    Kidney Int; 2019 Jul; 96(1):94-103. PubMed ID: 30987838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients.
    Chauvet S; Bridoux F; Ecotière L; Javaugue V; Sirac C; Arnulf B; Thierry A; Quellard N; Milin S; Bender S; Goujon JM; Jaccard A; Fermand JP; Touchard G
    Am J Kidney Dis; 2015 Nov; 66(5):756-67. PubMed ID: 25987261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
    Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
    Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients.
    Lin P; Bueso-Ramos C; Wilson CS; Mansoor A; Medeiros LJ
    Am J Surg Pathol; 2003 Aug; 27(8):1104-13. PubMed ID: 12883242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.
    Kristinsson SY; Björkholm M; Goldin LR; McMaster ML; Turesson I; Landgren O
    Blood; 2008 Oct; 112(8):3052-6. PubMed ID: 18703425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal MALT lymphoma associated with Waldenström macroglobulinemia.
    Chi PJ; Pei SN; Huang TL; Huang SC; Ng HY; Lee CT
    J Formos Med Assoc; 2014 Apr; 113(4):255-7. PubMed ID: 24685302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.
    Cao XX; Meng Q; Mao YY; Su W; Zhen JF; Shen KN; Zhang CL; Huang XF; Duan MH; Zhang W; Zhu TN; Cai HC; Chen M; Zhou DB; Li J
    Leuk Res; 2016 Jul; 46():85-8. PubMed ID: 27232065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nodal lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: a clinicopathological and prognostical study].
    Zhang DD; Hu PZ; Li P; Jiang GZ; Yin YH; Wang GN; Zhao WG; Zhang YP; Li WC
    Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):592-597. PubMed ID: 34078045
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Gomez Mediavilla A; Urquieta Lam M; Insunza A; Tonda R; Beltran S; Gut M; Gonzalez A; Montes-Moreno S
    J Clin Pathol; 2020 Sep; 73(9):571-577. PubMed ID: 31980558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
    Tedeschi A; Conticello C; Rizzi R; Benevolo G; Laurenti L; Petrucci MT; Zaja F; Varettoni M
    Hematol Oncol; 2019 Apr; 37(2):117-128. PubMed ID: 30192023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?
    Berger F; Traverse-Glehen A; Felman P; Callet-Bauchu E; Baseggio L; Gazzo S; Thieblemont C; Ffrench M; Magaud JP; Salles G; Coiffer B
    Clin Lymphoma; 2005 Mar; 5(4):220-4. PubMed ID: 15794852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
    Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
    Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario.
    Danesin N; Scapinello G; Del Prete D; Naso E; Berno T; Visentin A; Bonaldi L; Martines A; Bertorelle R; Vianello F; Gurrieri C; Zambello R; Castellani C; Fedrigo M; Rizzo S; Angelini A; Trentin L; Piazza F
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2062. PubMed ID: 38662353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.
    Varettoni M; Zibellini S; Capello D; Arcaini L; Rossi D; Pascutto C; Rattotti S; Mangiacavalli S; Pochintesta L; Gotti M; Gaidano G; Cazzola M
    Leuk Lymphoma; 2013 Nov; 54(11):2485-9. PubMed ID: 23442064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological correlates of IgM paraproteinemias.
    Owen RG; Parapia LA; Higginson J; Misbah SA; Child JA; Morgan GJ; Jack AS
    Clin Lymphoma; 2000 Jun; 1(1):39-43; discussion 44-5. PubMed ID: 11707811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
    Xu L; Hunter ZR; Yang G; Zhou Y; Cao Y; Liu X; Morra E; Trojani A; Greco A; Arcaini L; Varettoni M; Brown JR; Tai YT; Anderson KC; Munshi NC; Patterson CJ; Manning RJ; Tripsas CK; Lindeman NI; Treon SP
    Blood; 2013 Mar; 121(11):2051-8. PubMed ID: 23321251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.